CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Reimbursement Status of Newer Drugs for the Treatment of Type 2 Diabetes

Last updated: February 27, 2019
Project Number: ES0337-000
Product Line: Environmental Scans
Result type: Report

This project aims to retrieve and summarize the formulary status of drugs pertaining to three classes used for the treatment of type 2 diabetes; i.e., dipeptidyl-peptidase 4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and glucagon-like peptide 1 (GLP-1) agonists. Information will be retrieved from the website of all publicly funded provincial, territorial, and federal drug plans in Canada.